title: Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
abstract: BACKGROUND
  our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC).
  
  
  METHODS
  five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection.
  
  
  RESULTS
  the mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 ± 0.46 to 0.17 ± 0.47 and the mean central foveal thickness significantly decreased from 323 ± 98 microm to 171 ± 63 microm (p < 0.05).
  
  
  CONCLUSIONS
  The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination.
authors.affiliation: Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan. maicoo @ urahp.yokohama-cu.ac.jp
authors.forename: Maiko
authors.initials: M
authors.lastname: Inoue
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Shin
authors.initials: S
authors.lastname: Yamane
authors.forename: Akira
authors.initials: A
authors.lastname: Arakawa
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D012163:Retinal Detachment / Q000517:prevention & control; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab